25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

IBRX (Immunitybio) Stock Analysis
Buy, Hold or Sell?

Let's analyze Immunitybio together

I guess you are interested in Immunitybio Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Immunitybioโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Immunitybioโ€™s Price Targets

I'm going to help you getting a better view of Immunitybio Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Immunitybio Inc

I send you an email if I find something interesting about Immunitybio Inc.

1. Quick Overview

1.1. Quick analysis of Immunitybio (30 sec.)










1.2. What can you expect buying and holding a share of Immunitybio? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$-0.67
Expected worth in 1 year
$-0.56
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$0.11
Return On Investment
4.1%

For what price can you sell your share?

Current Price per Share
$2.81
Expected price per share
$1.85 - $4.43
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Immunitybio (5 min.)




Live pricePrice per Share (EOD)
$2.81
Intrinsic Value Per Share
$-1.47 - $-1.58
Total Value Per Share
$-2.14 - $-2.25

2.2. Growth of Immunitybio (5 min.)




Is Immunitybio growing?

Current yearPrevious yearGrowGrow %
How rich?-$590.4m-$583.1m-$46.8m-7.4%

How much money is Immunitybio making?

Current yearPrevious yearGrowGrow %
Making money-$102.2m-$150.2m$47.9m46.9%
Net Profit Margin-3,956.2%-239,008.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Immunitybio (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#870 / 872

Most Revenue
#312 / 872

Most Profit
#843 / 872

Most Efficient
#793 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Immunitybio?

Welcome investor! Immunitybio's management wants to use your money to grow the business. In return you get a share of Immunitybio.

First you should know what it really means to hold a share of Immunitybio. And how you can make/lose money.

Speculation

The Price per Share of Immunitybio is $2.81. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immunitybio.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immunitybio, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.67. Based on the TTM, the Book Value Change Per Share is $0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immunitybio.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-5.2%-0.12-4.1%-0.17-6.1%-0.14-4.8%-0.11-4.0%-0.07-2.6%
Usd Book Value Change Per Share-0.12-4.1%0.031.0%-0.05-1.6%-0.02-0.8%-0.04-1.4%-0.02-0.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.12-4.1%0.031.0%-0.04-1.6%-0.02-0.8%-0.04-1.4%-0.02-0.6%
Usd Price Per Share3.01-3.90-3.72-3.84-6.90-5.95-
Price to Earnings Ratio-5.12--8.65--5.48--7.41--26.45--31.19-
Price-to-Total Gains Ratio-25.96--239.90--21.43--161.60--95.70--189.61-
Price to Book Ratio-4.50--5.38--5.46--6.20--20.76--2.94-
Price-to-Total Gains Ratio-25.96--239.90--21.43--161.60--95.70--189.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.81
Number of shares355
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.03-0.04
Usd Total Gains Per Share0.03-0.04
Gains per Quarter (355 shares)10.11-13.90
Gains per Year (355 shares)40.42-55.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1040300-56-66
2081700-112-122
301211101-167-178
401621501-223-234
502021901-279-290
602432301-335-346
702832701-390-402
803233101-446-458
903643502-502-514
1004043902-558-570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.040.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%9.031.00.022.5%9.031.00.022.5%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.016.020.0%6.00.034.015.0%6.00.034.015.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%5.015.00.025.0%9.031.00.022.5%9.031.00.022.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Immunitybio Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1160.028-507%-0.045-61%-0.024-79%-0.039-66%-0.017-86%
Book Value Per Share---0.669-0.714+7%-0.661-1%-0.631-6%-0.450-33%-0.105-84%
Current Ratio--2.2193.041-27%2.794-21%2.179+2%2.084+6%8.070-73%
Debt To Asset Ratio--2.9442.707+9%2.513+17%2.518+17%2.169+36%1.185+149%
Debt To Equity Ratio----0%-0%-0%0.008-100%0.068-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%0.000-100%
Enterprise Value--1824036296.3202580426674.880-29%2456728918.880-26%2590273539.467-30%5500030115.872-67%5142420444.152-65%
Eps---0.147-0.116-21%-0.170+16%-0.136-7%-0.111-24%-0.073-50%
Ev To Ebitda Ratio---7.078-13.973+97%-5.655-20%-9.372+32%-20.612+191%-31.124+340%
Ev To Sales Ratio--27.608321.070-91%10610.147-100%6986.682-100%11990.748-100%61915.506-100%
Free Cash Flow Per Share---0.099-0.107+8%-0.117+19%-0.113+15%-0.100+2%-0.059-40%
Free Cash Flow To Equity Per Share---0.100-0.030-70%0.022-547%-0.012-88%-0.002-98%0.000-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.576----------
Intrinsic Value_10Y_min---1.473----------
Intrinsic Value_1Y_max---0.410----------
Intrinsic Value_1Y_min---0.403----------
Intrinsic Value_3Y_max---1.039----------
Intrinsic Value_3Y_min---0.996----------
Intrinsic Value_5Y_max---1.437----------
Intrinsic Value_5Y_min---1.351----------
Market Cap2480162289.920-7%2656686296.3203444424674.880-23%3278933418.880-19%3387054372.800-22%6092064115.872-56%5255671308.048-49%
Net Profit Margin---7.849-39.562+404%-2390.085+30350%-1272.089+16107%-1254.805+15886%-1970.778+25008%
Operating Margin----25.3980%-1795.5620%-990.2230%-1056.7390%-1873.2310%
Operating Ratio--4.90132.472-85%1563.956-100%935.794-99%1038.739-100%1897.600-100%
Pb Ratio-4.200+7%-4.499-5.385+20%-5.464+21%-6.197+38%-20.762+361%-2.937-35%
Pe Ratio-4.783+7%-5.123-8.652+69%-5.483+7%-7.408+45%-26.453+416%-31.191+509%
Price Per Share2.810-7%3.0103.903-23%3.715-19%3.838-22%6.902-56%5.955-49%
Price To Free Cash Flow Ratio-7.125+7%-7.632-8.997+18%-7.722+1%-8.369+10%-21.065+176%-57.307+651%
Price To Total Gains Ratio-24.231+7%-25.956-239.895+824%-21.428-17%-161.599+523%-95.699+269%-189.608+630%
Quick Ratio--1.6172.994-46%2.723-41%2.108-23%2.138-24%11.577-86%
Return On Assets---0.427-0.280-34%-0.373-13%-0.330-23%-0.335-22%-0.239-44%
Return On Equity----0%-0%-0%-0.0150%-0.0830%
Total Gains Per Share---0.1160.028-507%-0.045-61%-0.024-80%-0.039-66%-0.017-86%
Usd Book Value---590482000.000-630037750.000+7%-583187000.000-1%-557124166.667-6%-397355550.000-33%-92320750.000-84%
Usd Book Value Change Per Share---0.1160.028-507%-0.045-61%-0.024-79%-0.039-66%-0.017-86%
Usd Book Value Per Share---0.669-0.714+7%-0.661-1%-0.631-6%-0.450-33%-0.105-84%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%0.000-100%
Usd Enterprise Value--1824036296.3202580426674.880-29%2456728918.880-26%2590273539.467-30%5500030115.872-67%5142420444.152-65%
Usd Eps---0.147-0.116-21%-0.170+16%-0.136-7%-0.111-24%-0.073-50%
Usd Free Cash Flow---87026000.000-94226750.000+8%-103211500.000+19%-99657083.333+15%-88467200.000+2%-52401250.000-40%
Usd Free Cash Flow Per Share---0.099-0.107+8%-0.117+19%-0.113+15%-0.100+2%-0.059-40%
Usd Free Cash Flow To Equity Per Share---0.100-0.030-70%0.022-547%-0.012-88%-0.002-98%0.000-100%
Usd Market Cap2480162289.920-7%2656686296.3203444424674.880-23%3278933418.880-19%3387054372.800-22%6092064115.872-56%5255671308.048-49%
Usd Price Per Share2.810-7%3.0103.903-23%3.715-19%3.838-22%6.902-56%5.955-49%
Usd Profit---129646000.000-102275250.000-21%-150240500.000+16%-122923083.333-5%-105475300.000-19%-68411375.000-47%
Usd Revenue--16517000.0007805500.000+112%75500.000+21777%2675833.333+517%1674900.000+886%871700.000+1795%
Usd Total Gains Per Share---0.1160.028-507%-0.045-61%-0.024-80%-0.039-66%-0.017-86%
 EOD+2 -6MRQTTM+12 -22YOY+10 -263Y+10 -265Y+11 -2610Y+8 -30

3.3 Fundamental Score

Let's check the fundamental score of Immunitybio Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.783
Price to Book Ratio (EOD)Between0-1-4.200
Net Profit Margin (MRQ)Greater than0-7.849
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.617
Current Ratio (MRQ)Greater than12.219
Debt to Asset Ratio (MRQ)Less than12.944
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.427
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Immunitybio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.318
Ma 20Greater thanMa 502.811
Ma 50Greater thanMa 1002.699
Ma 100Greater thanMa 2002.794
OpenGreater thanClose2.880
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Immunitybio Inc

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guรฉrin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Fundamental data was last updated by Penke on 2025-07-11 06:15:08.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Immunitybio earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareย Immunitybio to theย Biotechnology industry mean.
  • A Net Profit Margin of -784.9%ย means thatย $-7.85 for each $1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immunitybio Inc:

  • The MRQ is -784.9%. The company is making a huge loss. -2
  • The TTM is -3,956.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-784.9%TTM-3,956.2%+3,171.2%
TTM-3,956.2%YOY-239,008.5%+235,052.3%
TTM-3,956.2%5Y-125,480.5%+121,524.3%
5Y-125,480.5%10Y-197,077.8%+71,597.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-784.9%-91.7%-693.2%
TTM-3,956.2%-140.3%-3,815.9%
YOY-239,008.5%-196.4%-238,812.1%
3Y-127,208.9%-247.9%-126,961.0%
5Y-125,480.5%-343.3%-125,137.2%
10Y-197,077.8%-488.1%-196,589.7%
4.3.1.2. Return on Assets

Shows howย efficientย Immunitybio is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Immunitybio to theย Biotechnology industry mean.
  • -42.7% Return on Assets means thatย Immunitybio generatedย $-0.43 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immunitybio Inc:

  • The MRQ is -42.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -28.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-42.7%TTM-28.0%-14.7%
TTM-28.0%YOY-37.3%+9.3%
TTM-28.0%5Y-33.5%+5.5%
5Y-33.5%10Y-23.9%-9.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-42.7%-11.5%-31.2%
TTM-28.0%-11.5%-16.5%
YOY-37.3%-11.4%-25.9%
3Y-33.0%-11.7%-21.3%
5Y-33.5%-11.9%-21.6%
10Y-23.9%-13.7%-10.2%
4.3.1.3. Return on Equity

Shows how efficient Immunitybio is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Immunitybio to theย Biotechnology industry mean.
  • 0.0% Return on Equity means Immunitybio generated $0.00ย for eachย $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immunitybio Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1.5%+1.5%
5Y-1.5%10Y-8.3%+6.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--14.8%+14.8%
YOY--14.4%+14.4%
3Y--16.8%+16.8%
5Y-1.5%-17.5%+16.0%
10Y-8.3%-19.5%+11.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Immunitybio Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Immunitybio is operatingย .

  • Measures how much profit Immunitybio makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Immunitybio to theย Biotechnology industry mean.
  • An Operating Margin of 0.0%ย means the company generated $0.00 ย for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immunitybio Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,539.8%+2,539.8%
TTM-2,539.8%YOY-179,556.2%+177,016.4%
TTM-2,539.8%5Y-105,673.9%+103,134.1%
5Y-105,673.9%10Y-187,323.1%+81,649.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--221.8%+221.8%
TTM-2,539.8%-250.7%-2,289.1%
YOY-179,556.2%-208.5%-179,347.7%
3Y-99,022.3%-220.2%-98,802.1%
5Y-105,673.9%-342.4%-105,331.5%
10Y-187,323.1%-462.5%-186,860.6%
4.3.2.2. Operating Ratio

Measures how efficient Immunitybio is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Biotechnology industry mean).
  • An Operation Ratio of 4.90 means that the operating costs are $4.90 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immunitybio Inc:

  • The MRQ is 4.901. The company is inefficient in keeping operating costs low. -1
  • The TTM is 32.472. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.901TTM32.472-27.571
TTM32.472YOY1,563.956-1,531.484
TTM32.4725Y1,038.739-1,006.267
5Y1,038.73910Y1,897.600-858.861
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9012.097+2.804
TTM32.4722.684+29.788
YOY1,563.9563.076+1,560.880
3Y935.7943.524+932.270
5Y1,038.7394.724+1,034.015
10Y1,897.6006.445+1,891.155
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Immunitybio Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Immunitybio is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Biotechnology industry mean).
  • A Current Ratio of 2.22ย means the company has $2.22 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immunitybio Inc:

  • The MRQ is 2.219. The company is able to pay all its short-term debts. +1
  • The TTM is 3.041. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.219TTM3.041-0.822
TTM3.041YOY2.794+0.247
TTM3.0415Y2.084+0.957
5Y2.08410Y8.070-5.986
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2193.638-1.419
TTM3.0413.846-0.805
YOY2.7944.140-1.346
3Y2.1794.688-2.509
5Y2.0845.722-3.638
10Y8.0706.144+1.926
4.4.3.2. Quick Ratio

Measures if Immunitybio is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Immunitybio to theย Biotechnology industry mean.
  • A Quick Ratio of 1.62ย means the company can pay off $1.62 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immunitybio Inc:

  • The MRQ is 1.617. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.994. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.617TTM2.994-1.377
TTM2.994YOY2.723+0.270
TTM2.9945Y2.138+0.856
5Y2.13810Y11.577-9.439
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6172.826-1.209
TTM2.9943.116-0.122
YOY2.7233.786-1.063
3Y2.1084.311-2.203
5Y2.1385.702-3.564
10Y11.5776.335+5.242
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Immunitybio Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Immunitybioย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Immunitybio to Biotechnology industry mean.
  • A Debt to Asset Ratio of 2.94ย means that Immunitybio assets areย financed with 294.4% credit (debt) and the remaining percentage (100% - 294.4%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Immunitybio Inc:

  • The MRQ is 2.944. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 2.707. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ2.944TTM2.707+0.237
TTM2.707YOY2.513+0.195
TTM2.7075Y2.169+0.539
5Y2.16910Y1.185+0.984
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9440.327+2.617
TTM2.7070.349+2.358
YOY2.5130.332+2.181
3Y2.5180.340+2.178
5Y2.1690.346+1.823
10Y1.1850.378+0.807
4.5.4.2. Debt to Equity Ratio

Measures ifย Immunitybio is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Immunitybio to theย Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immunitybio Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.008-0.008
5Y0.00810Y0.068-0.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.383-0.383
TTM-0.438-0.438
YOY-0.414-0.414
3Y-0.450-0.450
5Y0.0080.457-0.449
10Y0.0680.512-0.444
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every $1 in earnings Immunitybio generates.

  • Above 15 is considered overpriced butย always compareย Immunitybio to theย Biotechnology industry mean.
  • A PE ratio of -5.12 means the investor is paying $-5.12ย for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immunitybio Inc:

  • The EOD is -4.783. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.123. Based on the earnings, the company is expensive. -2
  • The TTM is -8.652. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.783MRQ-5.123+0.340
MRQ-5.123TTM-8.652+3.529
TTM-8.652YOY-5.483-3.169
TTM-8.6525Y-26.453+17.801
5Y-26.45310Y-31.191+4.738
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.783-2.399-2.384
MRQ-5.123-2.092-3.031
TTM-8.652-2.625-6.027
YOY-5.483-3.784-1.699
3Y-7.408-3.762-3.646
5Y-26.453-6.363-20.090
10Y-31.191-7.055-24.136
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immunitybio Inc:

  • The EOD is -7.125. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.632. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.997. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.125MRQ-7.632+0.507
MRQ-7.632TTM-8.997+1.365
TTM-8.997YOY-7.722-1.274
TTM-8.9975Y-21.065+12.069
5Y-21.06510Y-57.307+36.242
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.125-3.299-3.826
MRQ-7.632-2.742-4.890
TTM-8.997-3.801-5.196
YOY-7.722-4.402-3.320
3Y-8.369-5.140-3.229
5Y-21.065-8.483-12.582
10Y-57.307-9.296-48.011
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Immunitybio is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Biotechnology industry mean).
  • A PB ratio of -4.50 means the investor is paying $-4.50ย for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immunitybio Inc:

  • The EOD is -4.200. Based on the equity, the company is expensive. -2
  • The MRQ is -4.499. Based on the equity, the company is expensive. -2
  • The TTM is -5.385. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.200MRQ-4.499+0.299
MRQ-4.499TTM-5.385+0.886
TTM-5.385YOY-5.464+0.079
TTM-5.3855Y-20.762+15.377
5Y-20.76210Y-2.937-17.825
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.2002.113-6.313
MRQ-4.4991.856-6.355
TTM-5.3852.125-7.510
YOY-5.4642.454-7.918
3Y-6.1972.492-8.689
5Y-20.7623.668-24.430
10Y-2.9374.364-7.301
4.6.2. Total Gains per Share

2.4. Latest News of Immunitybio Inc

Does Immunitybio Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Immunitybio Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-11
19:38
Exploring 3 High Growth Tech Stocks In The US MarketRead
2025-07-09
14:30
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat CancersRead
2025-06-24
21:51
ImmunityBio (IBRX) Attains FDAโ€™s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVARead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Immunitybio Inc.

4.8.1. Institutions holding Immunitybio Inc

Institutions are holding 9.239% of the shares of Immunitybio Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Group Inc2.30510.001120344554301632517.407
2025-03-31BlackRock Inc1.50580.000813290056-294686-2.1692
2025-03-31State Street Corp0.85930.00097583901-2201256-22.4959
2025-03-31Geode Capital Management, LLC0.4860.001428942044850211.6769
2025-03-31Woodline Partners LP0.39030.0674344509726570.0772
2025-03-31Citigroup Inc0.30760.004227146622330086605.8844
2025-03-31TANG CAPITAL MANAGEMENT LLC0.26440.38862333333-480859-17.0869
2025-03-31Morgan Stanley - Brokerage Accounts0.21470.00041895134-2110680-52.6904
2025-03-31UBS Group AG0.1630.00081438416-149273-9.4019
2025-03-31Northern Trust Corp0.15390.00061358142347182.6233
2025-03-31Group One Trading, LP0.15250.01181346036847607170.0557
2025-03-31Charles Schwab Investment Management Inc0.14750.00071302083254101.9903
2025-03-31Goldman Sachs Group Inc0.11980.00051056899-84637-7.4143
2025-03-31JPMorgan Chase & Co0.11550.00021018954-22909-2.1988
2025-03-31BSC Private Wealth Management, LLC0.09590.246284641900
2025-03-31Verition Fund Managegment, LLC0.09370.01168270397767091543.2327
2025-03-31Susquehanna International Group, LLP0.08760.000477347120956037.1619
2025-03-31Allen Holding Inc0.07790.215368757100
2025-03-31Sheets Smith Wealth Management0.07180.2369633475-500-0.0789
2025-03-31Accurate Wealth Management, LLC0.06350.281156000000
Total 7.67581.470567744662+2346774+3.5%

4.9.2. Funds holding Immunitybio Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Vanguard Total Stock Mkt Idx Inv0.84420.0011745080500
2025-05-31Vanguard Small Cap Index0.60720.00965359243195870.3668
2025-05-31iShares Russell 2000 ETF0.42970.0164379220000
2025-05-31SPDRยฎ S&P Biotech ETF0.42310.21173734503220920.5951
2025-05-31Vanguard Small Cap Growth Index Inv0.33480.02222954925-3898-0.1317
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.29440.00632598186210520.8169
2025-03-31Fidelity Small Cap Index0.17310.0191527834836455.7918
2025-05-31iShares Russell 2000 Growth ETF0.11610.0247102431400
2025-04-30Fidelity Extended Market Index0.10440.0064921722-8810-0.9468
2025-05-31State St Russell Sm/Mid Cpยฎ Indx SL Cl I0.09970.005787998200
2025-05-31JPM Thematics Genetic Thrps C2 dist USD0.0930.6269820924-8157-0.9839
2025-05-31Schwab US Small-Cap ETFโ„ข0.08940.0127788822-2109-0.2666
2025-05-31Vanguard Russell 2000 ETF0.08760.016277275268370.8927
2025-05-31Vanguard Health Care ETF0.07820.0105689971265003.9941
2025-05-31iShares Biotechnology ETF0.05870.027651769800
2025-05-31State St Russell Sm Capยฎ Indx SL Cl I0.0580.015751165200
2025-04-30Fidelity Nasdaq Composite Index0.04530.00639952200
2025-05-31Schwab Small Cap Index0.0430.016337947300
2025-03-31NT R2000 Index Fund - NL0.04170.019368416297428.7819
2025-03-31Extended Equity Market Fund K0.04060.00813581595620918.6153
Total 4.06221.082135851103+242690+0.7%

5.3. Insider Transactions

Insiders are holding 74.109% of the shares of Immunitybio Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-05Michael D BlaszykBUY719152.75
2023-06-02John Owen BrennanBUY250002.83
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Debt  762,387106,467868,854-237,908630,946-270,208360,738-380,841-20,103



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets303,759
Total Liabilities894,241
Total Stockholder Equity-590,482
 As reported
Total Liabilities 894,241
Total Stockholder Equity+ -590,482
Total Assets = 303,759

Assets

Total Assets303,759
Total Current Assets109,163
Long-term Assets194,596
Total Current Assets
Cash And Cash Equivalents 60,660
Short-term Investments 931
Net Receivables 17,029
Inventory 8,444
Other Current Assets 22,099
Total Current Assets  (as reported)109,163
Total Current Assets  (calculated)109,163
+/-0
Long-term Assets
Property Plant Equipment 167,050
Goodwill 910
Intangible Assets 14,533
Long-term Assets Other 12,103
Long-term Assets  (as reported)194,596
Long-term Assets  (calculated)194,596
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities49,205
Long-term Liabilities845,036
Total Stockholder Equity-590,482
Total Current Liabilities
Short-term Debt 7,460
Accounts payable 13,501
Other Current Liabilities 14,743
Total Current Liabilities  (as reported)49,205
Total Current Liabilities  (calculated)35,704
+/- 13,501
Long-term Liabilities
Long term Debt 485,717
Capital Lease Obligations 40,557
Long-term Liabilities Other 296,657
Long-term Liabilities  (as reported)845,036
Long-term Liabilities  (calculated)822,931
+/- 22,105
Total Stockholder Equity
Total Stockholder Equity (as reported)-590,482
Total Stockholder Equity (calculated)0
+/- 590,482
Other
Capital Stock85
Cash and Short Term Investments 61,591
Common Stock Shares Outstanding 853,162
Liabilities and Stockholders Equity 303,759
Net Debt -20,103
Net Invested Capital -105,714
Net Working Capital 59,958
Property Plant and Equipment Gross 269,985
Short Long Term Debt Total 40,557



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
60,828
58,456
132,557
370,191
366,849
357,428
342,935
332,411
317,496
303,675
301,620
277,737
250,440
229,845
211,433
201,641
181,950
208,261
175,696
160,207
123,538
127,023
196,164
116,865
221,381
209,428
246,301
214,421
468,910
389,587
317,717
352,943
362,356
343,400
291,227
432,419
504,452
400,679
444,325
364,570
382,933
303,759
303,759382,933364,570444,325400,679504,452432,419291,227343,400362,356352,943317,717389,587468,910214,421246,301209,428221,381116,865196,164127,023123,538160,207175,696208,261181,950201,641211,433229,845250,440277,737301,620303,675317,496332,411342,935357,428366,849370,191132,55758,45660,828
   > Total Current Assets 
59,373
49,952
120,870
360,287
297,540
225,535
217,959
214,471
205,145
195,948
181,557
156,853
132,458
126,802
110,093
100,570
88,772
113,430
87,048
71,613
76,677
44,125
115,287
78,544
111,713
99,572
113,731
94,452
334,347
212,341
114,990
143,092
140,577
113,486
66,825
215,082
294,084
195,722
242,830
163,150
184,586
109,163
109,163184,586163,150242,830195,722294,084215,08266,825113,486140,577143,092114,990212,341334,34794,452113,73199,572111,71378,544115,28744,12576,67771,61387,048113,43088,772100,570110,093126,802132,458156,853181,557195,948205,145214,471217,959225,535297,540360,287120,87049,95259,373
       Cash And Cash Equivalents 
59,104
49,854
120,437
358,616
175,908
63,250
38,223
31,404
8,083
13,596
39,039
20,920
23,872
11,196
16,122
15,310
16,821
22,279
17,279
18,291
60,293
16,952
102,698
56,997
34,915
44,679
83,958
64,524
181,101
36,385
61,900
104,161
104,641
88,481
43,506
177,963
265,453
133,035
130,104
111,966
143,428
60,660
60,660143,428111,966130,104133,035265,453177,96343,50688,481104,641104,16161,90036,385181,10164,52483,95844,67934,91556,997102,69816,95260,29318,29117,27922,27916,82115,31016,12211,19623,87220,92039,03913,5968,08331,40438,22363,250175,908358,616120,43749,85459,104
       Short-term Investments 
0
0
0
0
118,310
158,509
175,540
177,852
190,838
177,374
136,466
131,347
104,280
110,593
88,822
67,998
57,328
76,270
66,773
47,766
4,055
23,263
7,925
4,666
61,146
38,594
19,970
15,848
136,015
155,947
21,038
6,896
2,543
2,787
2,448
11,833
1,009
37,460
87,875
18,401
6,381
931
9316,38118,40187,87537,4601,00911,8332,4482,7872,5436,89621,038155,947136,01515,84819,97038,59461,1464,6667,92523,2634,05547,76666,77376,27057,32867,99888,822110,593104,280131,347136,466177,374190,838177,852175,540158,509118,3100000
       Net Receivables 
145
40
45
45
1,774
1,251
1,552
1,261
2,668
1,314
2,617
1,284
1,258
2,246
3,021
13,539
12,168
11,793
772
444
303
348
139
610
2,003
5,434
2,047
1,304
1,333
3,893
1,451
6,488
1,890
1,464
3,279
2,325
3,168
2,137
2,060
4,175
2,653
17,029
17,0292,6534,1752,0602,1373,1682,3253,2791,4641,8906,4881,4513,8931,3331,3042,0475,4342,00361013934830344477211,79312,16813,5393,0212,2461,2581,2842,6171,3142,6681,2611,5521,2511,774454540145
       Other Current Assets 
124
58
388
1,671
1,548
2,525
2,644
3,954
3,556
3,664
3,435
3,302
3,048
2,767
2,128
3,000
2,455
1,888
1,974
3,862
16,107
3,562
4,525
8,367
9,196
10,865
7,756
12,286
15,898
16,116
30,601
25,547
31,503
20,754
17,592
22,961
24,454
23,090
20,980
26,650
23,852
22,099
22,09923,85226,65020,98023,09024,45422,96117,59220,75431,50325,54730,60116,11615,89812,2867,75610,8659,1968,3674,5253,56216,1073,8621,9741,8882,4553,0002,1282,7673,0483,3023,4353,6643,5563,9542,6442,5251,5481,67138858124
   > Long-term Assets 
1,455
8,504
11,687
9,904
69,309
131,893
124,976
117,940
112,351
107,727
120,063
120,884
117,982
103,043
101,340
101,071
93,178
94,831
88,648
88,594
46,861
82,898
80,877
38,321
109,668
109,856
132,570
119,969
134,563
177,246
202,727
209,851
221,779
229,914
224,402
217,337
210,368
204,957
201,495
201,420
198,347
194,596
194,596198,347201,420201,495204,957210,368217,337224,402229,914221,779209,851202,727177,246134,563119,969132,570109,856109,66838,32180,87782,89846,86188,59488,64894,83193,178101,071101,340103,043117,982120,884120,063107,727112,351117,940124,976131,89369,3099,90411,6878,5041,455
       Property Plant Equipment 
211
224
310
1,414
6,147
7,765
10,074
17,008
19,268
22,884
60,218
74,471
76,726
76,826
78,211
77,273
76,885
81,076
77,602
74,564
27,776
69,594
69,022
29,547
90,679
99,322
117,253
103,977
119,167
141,114
167,548
176,870
189,447
198,356
194,042
187,810
182,683
178,752
175,792
174,231
170,457
167,050
167,050170,457174,231175,792178,752182,683187,810194,042198,356189,447176,870167,548141,114119,167103,977117,25399,32290,67929,54769,02269,59427,77674,56477,60281,07676,88577,27378,21176,82676,72674,47160,21822,88419,26817,00810,0747,7656,1471,414310224211
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
910
910
910
910910910000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,397
1,000
822
802
822
865
914
811
840
820
841
817
891
0
0
0
0
0
000008918178418208408119148658228028221,00011,397000000000000000000000000
       Intangible Assets 
835
8,028
7,620
7,164
7,292
6,844
6,396
5,948
5,086
4,521
3,956
3,391
2,826
2,260
1,695
1,130
565
565
0
0
12,074
0
0
1,438
1,463
1,665
1,555
1,564
1,420
22,349
21,738
20,471
20,003
19,502
18,992
18,467
17,093
16,572
16,058
15,569
15,023
14,533
14,53315,02315,56916,05816,57217,09318,46718,99219,50220,00320,47121,73822,3491,4201,5641,5551,6651,4631,4380012,074005655651,1301,6952,2602,8263,3913,9564,5215,0865,9486,3966,8447,2927,1647,6208,028835
       Long-term Assets Other 
409
252
3,757
1,326
55,870
117,284
108,506
94,984
87,997
80,322
55,889
43,022
38,430
23,957
21,434
22,668
15,728
4,504
1,793
4,777
-2,242
4,051
2,602
-1,917
7,079
495
553
538
7,201
12,756
6,024
12,510
6,629
12,056
3,774
3,427
2,488
2,691
2,641
10,710
11,957
12,103
12,10311,95710,7102,6412,6912,4883,4273,77412,0566,62912,5106,02412,7567,2015385534957,079-1,9172,6024,051-2,2424,7771,7934,50415,72822,66821,43423,95738,43043,02255,88980,32287,99794,984108,506117,28455,8701,3263,757252409
> Total Liabilities 
2,405
3,055
6,039
7,260
10,854
12,928
15,578
21,520
24,078
25,306
48,696
40,033
31,596
29,485
29,802
39,555
35,944
40,453
24,427
24,251
226,419
24,428
26,511
314,315
339,871
394,764
404,886
404,365
712,823
727,143
739,691
782,024
812,176
875,116
936,410
843,064
1,090,389
1,091,662
1,141,703
1,108,732
871,062
894,241
894,241871,0621,108,7321,141,7031,091,6621,090,389843,064936,410875,116812,176782,024739,691727,143712,823404,365404,886394,764339,871314,31526,51124,428226,41924,25124,42740,45335,94439,55529,80229,48531,59640,03348,69625,30624,07821,52015,57812,92810,8547,2606,0393,0552,405
   > Total Current Liabilities 
2,405
3,055
6,039
6,683
6,148
7,858
10,045
10,232
12,553
14,201
36,878
28,674
20,868
19,398
20,192
30,404
27,260
27,701
12,430
12,519
36,515
14,248
17,049
54,314
68,134
79,863
74,428
65,408
368,995
381,014
376,050
70,840
500,861
564,945
613,478
90,324
58,283
53,759
62,110
60,960
54,944
49,205
49,20554,94460,96062,11053,75958,28390,324613,478564,945500,86170,840376,050381,014368,99565,40874,42879,86368,13454,31417,04914,24836,51512,51912,43027,70127,26030,40420,19219,39820,86828,67436,87814,20112,55310,23210,0457,8586,1486,6836,0393,0552,405
       Short-term Debt 
265
0
0
235
228
203
197
192
187
182
0
0
166
0
0
0
0
0
0
0
0
0
0
11,250
5,015
5,727
3,057
3,072
302,247
303,119
301,488
1,365
434,551
474,322
524,496
4,363
5,244
6,082
6,249
7,033
7,466
7,460
7,4607,4667,0336,2496,0825,2444,363524,496474,322434,5511,365301,488303,119302,2473,0723,0575,7275,01511,25000000000001660018218719219720322823500265
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
299,236
299,612
300,084
0
431,901
471,478
518,512
0
0
0
0
0
0
0
0000000518,512471,478431,9010300,084299,612299,2360000000000000000000000000000
       Accounts payable 
1,131
1,231
3,180
4,947
2,085
1,105
3,303
2,245
4,045
4,280
4,271
9,485
5,865
3,566
5,502
3,525
2,793
2,804
1,927
2,115
7,051
3,148
3,971
10,120
11,510
20,097
19,153
15,120
11,418
9,832
18,053
20,237
21,016
33,573
25,488
19,818
9,195
13,869
20,317
9,945
6,725
13,501
13,5016,7259,94520,31713,8699,19519,81825,48833,57321,01620,23718,0539,83211,41815,12019,15320,09711,51010,1203,9713,1487,0512,1151,9272,8042,7933,5255,5023,5665,8659,4854,2714,2804,0452,2453,3031,1052,0854,9473,1801,2311,131
       Other Current Liabilities 
488
1,367
2,618
1,736
4,063
6,753
6,742
7,987
8,508
9,921
32,607
19,189
15,003
15,832
14,690
26,879
24,467
24,897
10,503
10,404
29,464
11,100
13,078
44,194
51,609
54,234
52,417
46,872
55,330
68,063
56,509
49,238
45,294
57,050
63,494
66,143
43,844
33,808
35,544
43,982
40,753
14,743
14,74340,75343,98235,54433,80843,84466,14363,49457,05045,29449,23856,50968,06355,33046,87252,41754,23451,60944,19413,07811,10029,46410,40410,50324,89724,46726,87914,69015,83215,00319,18932,6079,9218,5087,9876,7426,7534,0631,7362,6181,367488
   > Long-term Liabilities 
1,917
1,688
3,421
577
4,706
5,070
5,533
11,288
11,525
11,105
11,818
11,359
10,728
10,087
9,610
9,151
8,684
12,752
11,997
11,732
189,904
10,180
9,462
260,001
271,737
314,901
330,458
338,957
343,828
346,129
363,641
711,184
311,315
310,171
322,932
752,740
1,032,106
1,037,903
1,079,593
1,047,772
816,118
845,036
845,036816,1181,047,7721,079,5931,037,9031,032,106752,740322,932310,171311,315711,184363,641346,129343,828338,957330,458314,901271,737260,0019,46210,180189,90411,73211,99712,7528,6849,1519,61010,08710,72811,35911,81811,10511,52511,2885,5335,0704,7065773,4211,6881,917
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,283
0
0
0
1,562
1,061
1,090
1,075
411
450
452
569
22,029
18,199
28,272
0
0
0
0
0
0
0
000000028,27218,19922,0295694524504111,0751,0901,0611,5620008,28300000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
170
170
170
162
162
162
0
0
0
0
0
0
0
0
0
0
0
000000000001621621621701701700000000000000000000000000
> Total Stockholder Equity
58,423
55,401
126,518
362,931
355,995
344,500
327,357
310,891
293,418
278,369
252,924
237,704
218,844
200,360
181,631
162,086
146,006
167,808
151,269
135,956
-106,535
102,595
169,653
-199,570
-119,808
-185,787
-157,939
-188,498
-242,173
-335,644
-419,815
-426,699
-447,327
-528,983
-642,116
-411,717
-586,987
-692,012
-698,387
-744,162
-489,098
-590,482
-590,482-489,098-744,162-698,387-692,012-586,987-411,717-642,116-528,983-447,327-426,699-419,815-335,644-242,173-188,498-157,939-185,787-119,808-199,570169,653102,595-106,535135,956151,269167,808146,006162,086181,631200,360218,844237,704252,924278,369293,418310,891327,357344,500355,995362,931126,51855,40158,423
   Common Stock
3
3
7
8
8
8
8
8
8
8
8
8
8
8
8
8
8
10
10
10
63
10
11
63
38
38
39
39
40
40
40
40
42
43
44
67
67
68
69
0
85
0
08506968676744434240404040393938386311106310101088888888888888733
   Retained Earnings -3,504,894-3,375,248-3,316,086-3,230,357-3,095,793-2,961,684-2,728,292-2,632,710-2,494,831-2,378,488-2,270,273-2,159,335-2,064,747-1,961,921-1,870,662-1,783,033-1,694,745-1,615,131-822,674-700,666-680,574-729,617-646,550-630,969-613,786-594,981-577,413-553,778-526,046-498,713-471,455-447,486-412,628-387,063-358,876-324,405-281,026-250,376-172,723-130,004-45,566-12,741
   Accumulated Other Comprehensive Income 
-46
0
0
-50
-167
-203
-270
-596
-1,178
-1,798
-2,631
-3,278
-4,303
-1,000
-7,186
-9,315
-11,561
-11,937
-14,162
-16,385
18
-20,824
-23,068
-4
122
-38
37
53
4
-367
-110
-190
183
-33
-40
792
10
-7
-8
0
1,198
0
01,1980-8-710792-40-33183-190-110-36745337-38122-4-23,068-20,82418-16,385-14,162-11,937-11,561-9,315-7,186-1,000-4,303-3,278-2,631-1,798-1,178-596-270-203-167-5000-46
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
783,287
870,408
871,170
1,495,163
1,508,958
1,625,018
1,682,072
1,719,704
1,729,430
1,739,590
1,843,724
1,930,936
1,965,838
1,990,590
0
0
0
0
0
0
0
00000001,990,5901,965,8381,930,9361,843,7241,739,5901,729,4301,719,7041,682,0721,625,0181,508,9581,495,163871,170870,408783,287000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
71,207
100,964
256,515
535,646
606,530
625,721
652,024
670,355
681,651
692,787
703,033
712,429
721,852
727,398
742,587
748,806
752,540
793,521
796,390
798,881
623,001
803,983
893,376
623,045
1,495,163
1,508,958
1,625,018
1,682,072
1,719,704
1,729,430
1,739,590
1,843,724
1,930,936
1,965,838
1,990,590
2,315,716
2,374,620
2,403,720
2,531,909
2,571,924
2,884,867
0
02,884,8672,571,9242,531,9092,403,7202,374,6202,315,7161,990,5901,965,8381,930,9361,843,7241,739,5901,729,4301,719,7041,682,0721,625,0181,508,9581,495,163623,045893,376803,983623,001798,881796,390793,521752,540748,806742,587727,398721,852712,429703,033692,787681,651670,355652,024625,721606,530535,646256,515100,96471,207



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue14,745
Cost of Revenue-17,554
Gross Profit-2,809-2,809
 
Operating Income (+$)
Gross Profit-2,809
Operating Expense-358,927
Operating Income-344,182-361,736
 
Operating Expense (+$)
Research Development190,144
Selling General Administrative168,783
Selling And Marketing Expenses0
Operating Expense358,927358,927
 
Net Interest Income (+$)
Interest Income2,400
Interest Expense-154,327
Other Finance Cost-0
Net Interest Income-151,927
 
Pretax Income (+$)
Operating Income-344,182
Net Interest Income-151,927
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-413,564-274,719
EBIT - interestExpense = -413,645
-413,483
-259,237
Interest Expense154,327
Earnings Before Interest and Taxes (EBIT)-259,318-259,237
Earnings Before Interest and Taxes (EBITDA)-241,764
 
After tax Income (+$)
Income Before Tax-413,564
Tax Provision-0
Net Income From Continuing Ops-413,645-413,564
Net Income-413,564
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses358,927
Total Other Income/Expenses Net-69,463151,927
 

Technical Analysis of Immunitybio
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Immunitybio. The general trend of Immunitybio is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Immunitybio's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Immunitybio Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Immunitybio Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.76 < 4.27 < 4.43.

The bearish price targets are: 2.5 > 2.43 > 1.85.

Know someone who trades $IBRX? Share this with them.๐Ÿ‘‡

Immunitybio Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Immunitybio Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Immunitybio Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Immunitybio Inc. The current macd is -0.01073692.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Immunitybio price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Immunitybio. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Immunitybio price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Immunitybio Inc Daily Moving Average Convergence/Divergence (MACD) ChartImmunitybio Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Immunitybio Inc. The current adx is 16.64.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Immunitybio shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Immunitybio Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Immunitybio Inc. The current sar is 3.03140562.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Immunitybio Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Immunitybio Inc. The current rsi is 51.32. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Immunitybio Inc Daily Relative Strength Index (RSI) ChartImmunitybio Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Immunitybio Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Immunitybio price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Immunitybio Inc Daily Stochastic Oscillator ChartImmunitybio Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Immunitybio Inc. The current cci is 13.54.

Immunitybio Inc Daily Commodity Channel Index (CCI) ChartImmunitybio Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Immunitybio Inc. The current cmo is 5.33422876.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Immunitybio Inc Daily Chande Momentum Oscillator (CMO) ChartImmunitybio Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Immunitybio Inc. The current willr is -38.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Immunitybio is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Immunitybio Inc Daily Williams %R ChartImmunitybio Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Immunitybio Inc.

Immunitybio Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Immunitybio Inc. The current atr is 0.19131655.

Immunitybio Inc Daily Average True Range (ATR) ChartImmunitybio Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Immunitybio Inc. The current obv is 247,185,734.

Immunitybio Inc Daily On-Balance Volume (OBV) ChartImmunitybio Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Immunitybio Inc. The current mfi is 51.75.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Immunitybio Inc Daily Money Flow Index (MFI) ChartImmunitybio Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Immunitybio Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Immunitybio Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Immunitybio Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.318
Ma 20Greater thanMa 502.811
Ma 50Greater thanMa 1002.699
Ma 100Greater thanMa 2002.794
OpenGreater thanClose2.880
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Immunitybio with someone you think should read this too:
  • Are you bullish or bearish on Immunitybio? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Immunitybio? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Immunitybio Inc

I send you an email if I find something interesting about Immunitybio Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Immunitybio Inc.

Receive notifications about Immunitybio Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.